Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Veru stock

Own Veru stock in just a few minutes.

Veru Inc is a biotechnology business based in the US. Veru shares (VERU) are listed on the NASDAQ and all prices are listed in US Dollars. Veru employs 339 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Veru

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VERU – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Veru share price

Use our graph to track the performance of VERU stocks over time.

Veru shares at a glance

Information last updated 2021-04-23.
52-week range$2.34 - $24.57
50-day moving average $11.72
200-day moving average $8.53
Wall St. target price$23.60
PE ratio 391.5217
Dividend yield N/A (0%)
Earnings per share (TTM) $0.02

Buy Veru shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Veru stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Veru under- or over-valued?

Valuing Veru stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Veru's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Veru's P/E ratio

Veru's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 392x. In other words, Veru shares trade at around 392x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Veru's EBITDA

Veru's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.4 million.

The EBITDA is a measure of a Veru's overall financial performance and is widely used to measure a its profitability.

Veru financials

Revenue TTM $46.6 million
Operating margin TTM 4.11%
Gross profit TTM $30.8 million
Return on assets TTM 1.88%
Return on equity TTM 3.98%
Profit margin 3.34%
Book value $0.68
Market capitalisation $705.7 million

TTM: trailing 12 months

Shorting Veru shares

There are currently 1.9 million Veru shares held short by investors – that's known as Veru's "short interest". This figure is 16.6% down from 2.3 million last month.

There are a few different ways that this level of interest in shorting Veru shares can be evaluated.

Veru's "short interest ratio" (SIR)

Veru's "short interest ratio" (SIR) is the quantity of Veru shares currently shorted divided by the average quantity of Veru shares traded daily (recently around 1.6 million). Veru's SIR currently stands at 1.15. In other words for every 100,000 Veru shares traded daily on the market, roughly 1150 shares are currently held short.

However Veru's short interest can also be evaluated against the total number of Veru shares, or, against the total number of tradable Veru shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Veru's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Veru shares in existence, roughly 20 shares are currently held short) or 0.0303% of the tradable shares (for every 100,000 tradable Veru shares, roughly 30 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Veru.

Find out more about how you can short Veru stock.

Veru share dividends

We're not expecting Veru to pay a dividend over the next 12 months.

Veru share price volatility

Over the last 12 months, Veru's shares have ranged in value from as little as $2.34 up to $24.57. A popular way to gauge a stock's volatility is its "beta".

VERU.US volatility(beta: 0.74)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veru's is 0.7441. This would suggest that Veru's shares are less volatile than average (for this exchange).

Veru overview

Veru Inc. , an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U. N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer. Its drug candidates also comprise VERU-100, a gonadotropin-releasing hormone antagonist peptide formulation to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site